WIN 65579

Drug Profile

WIN 65579

Alternative Names: SR 265579

Latest Information Update: 08 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi-Synthelabo
  • Developer Chinoin; Sanofi Winthrop; Sanofi-Synthelabo
  • Class Bronchodilators
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Cardiovascular disorders

Most Recent Events

  • 27 Jan 2000 A preclinical study has been added to the Obstructive Airways Disease pharmacodynamics section
  • 31 Dec 1999 Preclinical development for Asthma in France (PO)
  • 31 Dec 1999 Preclinical development for Asthma in Hungary (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top